Gap finder

Search review questions

Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.

Population

Intervention or exposure

Comparison

Outcome

Any field or review title

Field or topic

Source

Review versions

1,956 questions in 143 reviews · Musculoskeletal

current versions

No studies 555 · 28.4%Ungraded 107 · 5.5%Very low 255 · 13%Low 555 · 28.4%Moderate 357 · 18.3%High 127 · 6.5%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Question	Effect	Evidence	Status / GRADE
Oral NSAIDs vs glucocorticoid injection Quality of life · Adults with lateral elbow pain Non‐steroidal anti‐inflammatory drugs (NSAIDs) for treating lateral elbow pain in adults (2013) · Cochrane	no estimate extracted	NR	No studies
Oral NSAIDs vs glucocorticoid injection Function/disability 10‐point Likert scale (lower score = less disability) · Adults with lateral elbow pain Non‐steroidal anti‐inflammatory drugs (NSAIDs) for treating lateral elbow pain in adults (2013) · Cochrane	no estimate extracted	1 study · 105 participants	Low
Oral NSAIDs vs glucocorticoid injection Withdrawal due to adverse events · Adults with lateral elbow pain Non‐steroidal anti‐inflammatory drugs (NSAIDs) for treating lateral elbow pain in adults (2013) · Cochrane	no estimate extracted	NR	No studies
Oral NSAIDs vs glucocorticoid injection Adverse events · Adults with lateral elbow pain Non‐steroidal anti‐inflammatory drugs (NSAIDs) for treating lateral elbow pain in adults (2013) · Cochrane	no estimate extracted	NR	No studies
Topical NSAIDs vs placebo Treatment success Fair, good or excellent effectiveness · Adults with lateral elbow pain Non‐steroidal anti‐inflammatory drugs (NSAIDs) for treating lateral elbow pain in adults (2013) · Cochrane	RR 1.49 [1.04, 2.14]	1 study · 85 participants	Low
Topical NSAIDs vs placebo Function/disability · Adults with lateral elbow pain Non‐steroidal anti‐inflammatory drugs (NSAIDs) for treating lateral elbow pain in adults (2013) · Cochrane	no estimate extracted	NR	No studies
Topical NSAIDs vs placebo Quality of life · Adults with lateral elbow pain Non‐steroidal anti‐inflammatory drugs (NSAIDs) for treating lateral elbow pain in adults (2013) · Cochrane	no estimate extracted	NR	No studies
Topical NSAIDs vs placebo Withdrawal due to adverse events · Adults with lateral elbow pain Non‐steroidal anti‐inflammatory drugs (NSAIDs) for treating lateral elbow pain in adults (2013) · Cochrane	no estimate extracted	4 studies · 185 participants	Low
Topical NSAIDs vs placebo Adverse events · Adults with lateral elbow pain Non‐steroidal anti‐inflammatory drugs (NSAIDs) for treating lateral elbow pain in adults (2013) · Cochrane	RR 1.55 [0.2, 12.14]	3 studies · 153 participants	Low
Oral NSAIDs vs placebo Pain 0 to 100 visual analogue scale and 10‐point Likert scale (lower score = less pain) · adults with lateral elbow pain Non‐steroidal anti‐inflammatory drugs (NSAIDs) for treating lateral elbow pain in adults (2013) · Cochrane	no estimate extracted	2 studies · 292 participants	Very low
Oral NSAIDs vs placebo Treatment success Fair, good or excellent effectiveness · adults with lateral elbow pain Non‐steroidal anti‐inflammatory drugs (NSAIDs) for treating lateral elbow pain in adults (2013) · Cochrane	RR 1.17 [0.82, 1.67]	1 study · 111 participants	Low
Oral NSAIDs vs placebo Quality of life · adults with lateral elbow pain Non‐steroidal anti‐inflammatory drugs (NSAIDs) for treating lateral elbow pain in adults (2013) · Cochrane	no estimate extracted	NR	No studies
MTX treated vs no MTX treated ASAS 40 · Patients with AS Methotrexate for ankylosing spondylitis (2013) · Cochrane	no estimate extracted	NR	No studies
MTX treated vs no MTX treated Partial remission · Patients with AS Methotrexate for ankylosing spondylitis (2013) · Cochrane	no estimate extracted	NR	No studies
MTX treated vs no MTX treated BASFI (score from 0 to 10, 0=excellent, 10=poor function) · Patients with AS Methotrexate for ankylosing spondylitis (2013) · Cochrane	no estimate extracted	1 study · 35 participants	Low
MTX treated vs no MTX treated X‐Ray of the spine · Patients with AS Methotrexate for ankylosing spondylitis (2013) · Cochrane	no estimate extracted	NR	No studies
MTX treated vs no MTX treated MRI · Patients with AS Methotrexate for ankylosing spondylitis (2013) · Cochrane	no estimate extracted	NR	No studies
MTX treated vs no MTX treated Serious adverse event · Patients with AS Methotrexate for ankylosing spondylitis (2013) · Cochrane	no estimate extracted	NR	No studies
MTX treated vs no MTX treated Withdrawal for any reason · Patients with AS Methotrexate for ankylosing spondylitis (2013) · Cochrane	RR 1.06 [0.07, 15.62]	1 study · 35 participants	Low
Intervention NR ACR50 American College of Rheumatology 50% improvement criteria · participants with rheumatoid arthritis and with a partial response to DMARDs Etanercept for the treatment of rheumatoid arthritis (2013) · Cochrane	RR 1.96 [1.33, 2.89]	4 studies · 1198 participants	Moderate
Intervention NR Reduction in disability score Health Assessment Questionnaire (mean improvement from baseline). Scale from: 0 to 3 · participants with rheumatoid arthritis and with partial response to MTX Etanercept for the treatment of rheumatoid arthritis (2013) · Cochrane	no estimate extracted	1 study · 89 participants	Moderate
Intervention NR Radiographic progression Total Sharp Score · participants with rheumatoid arthritis and with partial response to MTX Etanercept for the treatment of rheumatoid arthritis (2013) · Cochrane	no estimate extracted	0 studies · 0 participants	Ungraded
Intervention NR Withdrawals due to adverse events · participants with rheumatoid arthritis and with partial response to MTX Etanercept for the treatment of rheumatoid arthritis (2013) · Cochrane	RR 1.02 [0.1, 10.77]	1 study · 89 participants	Moderate
Intervention NR Serious adverse events · participants with rheumatoid arthritis and with partial response to MTX Etanercept for the treatment of rheumatoid arthritis (2013) · Cochrane	RR 0.25 [0.05, 1.31]	1 study · 89 participants	Moderate
Intervention NR Serious infections · participants with rheumatoid arthritis and with partial response to MTX Etanercept for the treatment of rheumatoid arthritis (2013) · Cochrane	no estimate extracted	0 studies · 0 participants	Ungraded
Intervention NR Etanercept (25 mg) + DMARD · participants with rheumatoid arthritis Etanercept for the treatment of rheumatoid arthritis (2013) · Cochrane	RR 1.52 [1.36, 1.7]	2 studies · 958 participants	High
Intervention NR Etanercept (10 mg) · participants with rheumatoid arthritis Etanercept for the treatment of rheumatoid arthritis (2013) · Cochrane	RR 0.76 [0.58, 0.99]	1 study · 423 participants	High
Intervention NR Etanercept (25 mg) · participants with rheumatoid arthritis Etanercept for the treatment of rheumatoid arthritis (2013) · Cochrane	RR 7.95 [2.94, 21.47]	1 study · 158 participants	High
Intervention NR Serious infections · participants with rheumatoid arthritis Etanercept for the treatment of rheumatoid arthritis (2013) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Outcome: ACR50 ‐ American College of Rheumatology Improvement Criteria · participants with rheumatoid arthritis Etanercept for the treatment of rheumatoid arthritis (2013) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Remission Achievement of disease activity score < 2.6 · participants with rheumatoid arthritis and with a partial response to DMARDs Etanercept for the treatment of rheumatoid arthritis (2013) · Cochrane	RR 1.92 [1.6, 2.31]	2 studies · 987 participants	High
Intervention NR Etanercept + DMARD vs. DMARD · participants with rheumatoid arthritis Etanercept for the treatment of rheumatoid arthritis (2013) · Cochrane	RR 2.82 [1.71, 4.68]	5 studies · 1118 participants	High
Intervention NR Etanercept vs. DMARD · participants with rheumatoid arthritis Etanercept for the treatment of rheumatoid arthritis (2013) · Cochrane	RR 1.17 [1.02, 1.35]	3 studies · 1112 participants	High
Intervention NR Etanercept + DMARD vs. Etanercept · participants with rheumatoid arthritis Etanercept for the treatment of rheumatoid arthritis (2013) · Cochrane	RR 1.44 [1.16, 1.79]	3 studies · 805 participants	Moderate
Intervention NR Etanercept (25 mg) + DMARD · participants with rheumatoid arthritis Etanercept for the treatment of rheumatoid arthritis (2013) · Cochrane	no estimate extracted	2 studies · 894 participants	High
Intervention NR Etanercept (10 mg) · participants with rheumatoid arthritis Etanercept for the treatment of rheumatoid arthritis (2013) · Cochrane	no estimate extracted	1 study · 425 participants	High
Intervention NR Etanercept (25 mg) · participants with rheumatoid arthritis Etanercept for the treatment of rheumatoid arthritis (2013) · Cochrane	no estimate extracted	1 study · 424 participants	High
Intervention NR Reduction in disability score Health Assessment Questionnaire. Scale from: 0 to 3 · participants with rheumatoid arthritis and with a partial response to DMARDs Etanercept for the treatment of rheumatoid arthritis (2013) · Cochrane	no estimate extracted	4 studies · 1227 participants	High
Intervention NR Radiographic progression Total Sharp Score Scale from: 0 to 448 · participants with rheumatoid arthritis and with a partial response to DMARDs Etanercept for the treatment of rheumatoid arthritis (2013) · Cochrane	no estimate extracted	2 studies · 903 participants	Moderate
Intervention NR Withdrawals due to adverse events · participants with rheumatoid arthritis and with a partial response to DMARDs Etanercept for the treatment of rheumatoid arthritis (2013) · Cochrane	RR 0.75 [0.57, 1]	4 studies · 1241 participants	Moderate
Intervention NR Serious adverse events · participants with rheumatoid arthritis and with a partial response to DMARDs Etanercept for the treatment of rheumatoid arthritis (2013) · Cochrane	RR 1.25 [0.74, 2.11]	4 studies · 1241 participants	Moderate
Intervention NR Serious infections · participants with rheumatoid arthritis and with a partial response to DMARDs Etanercept for the treatment of rheumatoid arthritis (2013) · Cochrane	RR 0.91 [0.54, 1.55]	3 studies · 1152 participants	High
Intervention NR ACR50 American College of Rheumatology improvement criteria · participants with rheumatoid arthritis and with partial response to MTX Etanercept for the treatment of rheumatoid arthritis (2013) · Cochrane	RR 11.69 [1.66, 82.47]	1 study · 89 participants	Moderate
Intervention NR Remission Disease activity score < 2.6 · participants with rheumatoid arthritis and with partial response to MTX Etanercept for the treatment of rheumatoid arthritis (2013) · Cochrane	no estimate extracted	0 studies · 0 participants	Ungraded
Posterior cruciate ligament retention vs sacrifice (all types of arthroplasty designs) Performance based measures ‐ Range of motion (possible range 0 (worst) to 140 (maximal) degrees) · Patients receiving total knee arthroplasty with or without posterior stabilised design for the treatment of… Retention versus sacrifice of the posterior cruciate ligament in total knee arthroplasty for treating… (2013) · Cochrane	no estimate extracted	NR	Low
Posterior cruciate ligament retention vs sacrifice (using the same arthroplasty design) Survival rate of the implant (Revision surgery reported) · Patients receiving total knee arthroplasty with or without resection of the posterior cruciate ligament for the… Retention versus sacrifice of the posterior cruciate ligament in total knee arthroplasty for treating… (2013) · Cochrane	no estimate extracted	NR	No studies
Posterior cruciate ligament retention vs sacrifice (using the same arthroplasty design) Health related quality of life measures and functional measures with validated instruments (WOMAC, range 0‐100, higher scores indicate worse pain, stiffness and functional limitations) · Patients receiving total knee arthroplasty with or without resection of the posterior cruciate ligament for the… Retention versus sacrifice of the posterior cruciate ligament in total knee arthroplasty for treating… (2013) · Cochrane	no estimate extracted	NR	No studies
Posterior cruciate ligament retention vs sacrifice (using the same arthroplasty design) Global assessment (patient) Patient satisfaction on scale 0 (not at all satisfied) to 10 (completely satisfied)) · Patients receiving total knee arthroplasty with or without resection of the posterior cruciate ligament for the… Retention versus sacrifice of the posterior cruciate ligament in total knee arthroplasty for treating… (2013) · Cochrane	no estimate extracted	NR	Low
Posterior cruciate ligament retention vs sacrifice (using the same arthroplasty design) Complications · Patients receiving total knee arthroplasty with or without resection of the posterior cruciate ligament for the… Retention versus sacrifice of the posterior cruciate ligament in total knee arthroplasty for treating… (2013) · Cochrane	no estimate extracted	NR	No studies
Posterior cruciate ligament retention vs sacrifice (using the same arthroplasty design) Re‐operation rate (not involving implant change, short and long term) · Patients receiving total knee arthroplasty with or without resection of the posterior cruciate ligament for the… Retention versus sacrifice of the posterior cruciate ligament in total knee arthroplasty for treating… (2013) · Cochrane	no estimate extracted	NR	No studies